PF 6459988

Drug Profile

PF 6459988

Alternative Names: PF-06459988; PF-6459988

Latest Information Update: 05 Feb 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Non-small cell lung cancer

Most Recent Events

  • 09 Jan 2015 Pfizer withdrew a phase I/II trial in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in USA, prior to enrolment (NCT02297425)
  • 14 Nov 2014 Preclinical trials in Non-small cell lung cancer in USA (PO) before November 2014
  • 14 Nov 2014 Pfizer plans a phase I/II trial in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in USA (NCT02297425)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top